Congresses and Meetings

Long term clinical outcomes, presented at last month’s Cardiovascular Research Technologies Conference suggest that Micell has found an optimal combination of rapid absorbable polymer, coupled with anti-restenotic drug, yielding impressive results at 18 months.

We like to support events that tickle out fancies and this is one. Langbuisson have organised a glittering array of speakers for this year’s Investing in Medical Technology event, and our readers can enjoy a discounted place.

Medical device integration solutions company Capsule Tech, Inc., is using the HIMSS event in Florida this week to announce the introduction of its SmartLinx™ Medical Device Information System.

It’s a clever idea to constrain inflation of a PTA balloon along its length, because it avoids the worry of local vessel dissection. Registry results, reported at LINC 2014 last week, suggest the Chocolate® device works in a variety of peripheral artery disease conditions.

J&J Subsidiary, Cordis Corporation has seen two-year data from its INNOVATION Trial presented at the 2014 Leipzig Interventional Course in Germany. Data from the study continues to demonstrate that the INCRAFT® System performs well in patients suffering from abdominal aortic aneurysms (AAA) two years after treatment.

Medtronic has taken the opportunity presented by this weeks Thoracic Society meeting to announce that it has gained U.S. FDA approval for its Valiant Captivia Thoracic Stent Graft System to be used in the treatment of type B aortic dissections.

A new study, presented at the 50th holding of the Society of Thoracic Surgeons in Orlando Florida this week, points to improved management of patients when employing digital chest drains, as compared with traditional methods.

Data presented at last week’s Cervical Spine Research Society annual meeting indicate that significant improvements in pain and functional outcomes achieved by 1.5 months in both groups were sustained at seven years.

New retrospective data presented at NANS 2013 this week show highly significant reduction in pain and high trial therapy success rate of Boston Scientific’s Precision Spectra in the treatment of chronic pain

Israeli device company, SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, has announced a strategic alliance with PENTAX Medical, an industry leader in endoscopic imaging.

German ophthalmic device company, Retina Implant AG, has seen results from its clinical trial that led to CE mark of the Alpha IMS subretinal implant, presented at the American Academy of Ophthalmology (AAO) annual meeting.

It’s American Heart Association(AHA) meeting week in Dallas, Texas, and cardiovascular regenerative medicine company BioCardia®, Inc. has updated us on trial results from its stem cell studies, as reported both at the congress and concurrently the Journal of the American Medical Association.

The annual medtechfest that is the Medica exhibition takes place next week, so expect a few press releases from companies eager to attract the attention of visitor and browser alike. One such, OJBio Ltd., will be using attendance at Medica to showcase the latest developments in its biosensor platform technology for the rapid point of care diagnosis of infectious diseases.

While all the big cardio companies are focusing on valves, one developer has come up with an innovative approach to accessing the operative site in a safe, quick and easy way. We update the first clinical case, which took place live during EACTS in October.

Medtronic is trumpeting quite a landmark with the publication of a first head-to-head randomized controlled trial of “third-generation” durable-polymer drug-eluting stents for the treatment of coronary artery disease in an “all-comers” patient population. Resolute Integrity’s greater longitudinal strength doesn’t seem to play out in better target vessel failure stats.

Four year results from a randomised study suggest Biosensors’ BioFreedom™ polymer free, drug coated stent, demonstrates similar outcomes as Boston Scientifics’ drug eluter, Taxus™ Liberté™. The conclusion is that BioFreedom seemingly represents a good option for patients not able to tolerate long term DAPT.